These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10702629)

  • 1. New trends in thromboxane and prostacyclin modulators.
    Dogné JM; de Leval X; Delarge J; David JL; Masereel B
    Curr Med Chem; 2000 Jun; 7(6):609-28. PubMed ID: 10702629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.
    Patscheke H
    Blut; 1990 May; 60(5):261-8. PubMed ID: 2190651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
    Dogné JM; de Leval X; Hanson J; Frederich M; Lambermont B; Ghuysen A; Casini A; Masereel B; Ruan KH; Pirotte B; Kolh P
    Curr Med Chem; 2004 May; 11(10):1223-41. PubMed ID: 15134516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
    Lakin KM; Makarov VA; Novikova NV; Tret'iak VM; Rukazenkov IuE
    Farmakol Toksikol; 1984; 47(2):67-79. PubMed ID: 6425078
    [No Abstract]   [Full Text] [Related]  

  • 8. New developments on thromboxane modulators.
    Dogné JM; Hanson J; de Leval X; Masereel B; Kolh P; Pirotte B
    Mini Rev Med Chem; 2004 Aug; 4(6):649-57. PubMed ID: 15279599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition.
    Patscheke H; Hornberger W; Zehender H
    Z Kardiol; 1990; 79 Suppl 3():151-4. PubMed ID: 2099038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression.
    Li M; Kuo L; Stallone JN
    Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2444-55. PubMed ID: 18310519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
    Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
    Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosynthesis and pharmacological modulation of thromboxane in humans.
    Patrono C
    Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
    Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
    Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.